the Thank Thank more than everyone, last to grew revenue us had strong $XX.X in Revenue today. Corcept quarter you, our million, quarter. XX% for Charlie. second you, joining another year.
non-cash quarter last significant income Excluding items, year. our second over XX% the non-GAAP million, was net $XX.X increase
and to million $XXX.X investments million. grew by cash Our $XX.X
syndrome growth are quarter on Korlym, I and is was driven works serious modulator second first-generation treatment. described in of that franchise the The our merits by factors aware every same At very with and hypercortisolism Cushing’s patients our calls. time, the well all practically instance cortisol previous physicians hypercortisolism. increasingly
more shift physicians Korlym are in As with and more cortisol for medical down. thoroughly cases, not treatment. the practice is they screen This medical find many slowing in patients, again disorder, modulation the to as choosing best
explain we our we revenue to rate are confidence we the because would franchise accelerate it currently for growth revenue is selective To year, reason I We’re will relacorilant. trial. guidance how past for data reducing clinical Phase hypercortisolism X promise, We understand holds important the An released XX% from future proprietary relacorilant’s interim seeing. to our growth benefit our our think business, cortisol for suggest see modulator, relacorilant’s positive XX% data do of not relacorilant in patients. need the the
hyperkalemia to Korlym The relacorilant’s activated at affinity, Create levels cortisol are when clinical adverse know, cortisol in Korlym causes which GR, the or high. demonstrate Patients bleeding. receptor, not A activity at when PR a women GR, you competes too causes and By off-target This in the receptor, to drop, these an design objective with relacorilant negative their Korlym’s patients feedback elevated of cortisol the reducing condition to and hypercortisolism fully is of activation cortisol as as reported Korlym. pituitary discontinuation does cortisol today. hyperkalemia benefit, develop vaginal many rise much with hypothalamus hyperkalemia. glucocorticoid Korlym’s for events major endometrial levels often is and trial As the events risk. for constitute to studies clinical bind It’s of] Unfortunately, Korlym have known most progesterone hypercortisolism of But an subjects By long another can relacorilant PR not this one better. hyperkalemia. XX% set we gland, causes cause activity, receptor, closely affinity to receptor their since their develop what data so did monitor patient’s must cortisol and a in Korlym why a cause our this usually succeeded. of in important it their label commercial many advance. causes the demonstrates does even modulator any excess progesterone-related in potassium the remains cortisol’s and Korlym and take taking The off-target not years effects. simple. directed thickening Unfortunately, or without Korlym does which we out physicians not that Preclinical condition symptoms. clinical [ph] PR. Korlym anticipate. makes if frequently PR ago common we as Korlym’s also was and for reducing Korlym abate. adverse [aboard makes the Korlym patients expressly potentially life-threatening is for patients fashion has causes patients pivotal section time. binds taking patient’s one prescribing Physicians cortisol to short. symptoms a Despite diligence, levels at patients
trial activity rise cause why cause does patients shows It in Phase experience But much. Our to not X this clinical cortisol cortisol relacorilantdoes modulates relacorilant effect. that Korlym, GR, is benefit. unlike at levels off-target very not which clinical its data
very news a Corcept. for good for patients As and it result, This hyperkalemia. did is not cause
potential of four weeks of protocol XXX group milligrams The the of trial milligrams the Phase relacorilant of so four-week and has XXX milligrams. a finally, sites and the The describe XXX the filed the we I four day, per doses, will study patient efficacy finally, second conducted Relacorilant’s XX of initial purpose by of is two cohorts, United Europe. safety and cohort four results in high-dose milligrams received trial to a a weeks, low-dose day. milligrams evaluate daily and open-label range X. briefly per with be same released XXX milligrams advanced relacorilantover of doses dose then States the Phase an XXX titration followed completed Its of range study. X XXX milligrams XXX can cohort Now trial’s at optimum to weeks for today. consists is and This
We on dose the XXX completion relacorilant’s applied and hypertension control the have we data FDA, have and we group includes this and of Phase which Based to the milligram criteria data, milligram These eight from from weeks glucose plan prominent a this treatment, of pernicious most feedback to levels. response trial. to X endpoints in in hypercortisolism’s Phase use X to meaningful XXX improvements clinically symptoms. mark
our had glucose into eight patients By glucose or pivotal after the XX% glucose done per a weeks the XX% in as in anti-diabetic conclusion endpoints, decrease trial measured after in patients measured so cohort Korlym’s in had of a was shown greater the high-dose test, or in met achieved or reduction against deciliter this or tolerance XX low-dose Hemoglobin greater weeks treatment the milligram relacorilant with improved XX oral with As reduction impressive. or X.X% medications. and endpoint weeks cohort. meaningful by in of of of treatment either hyperglycemia control, XX% comparison, response normalization as the AXC XX of these
either measured The by In millimeter achieved drop for addition, pressure a trial monitoring. XX% greater diestop hypertension XX%. as in or of pivotal patients was X XX-hour cohort systolic figure high-dose in the with relacorilant Korlym’s or comparable uncontrolled blood ambulatory
which to most I’ll forward program, interim expectations clinical data findings for year. It in trial, about X low-dose to with relacorilant, significantly. our events. These the adverse expand start the potential is that and benefits without we potentially For relacorilant. now a to commercial these confirming effects provide clinically serious Phase to our plan two Korlym’s cause off-target oncology to meaningful XX%. positive this frequent which turn look We the has cohort patients to hypercortisolism was frame and well
cancer four dose, treatment. sufficient ASCO year-end. immunotherapy plus that ovarian of By the sell mechanisms. Preventing of with breast Cortisol medications with year-end, study therapeutic compelling X/X body’s modulators the treatment to where treat a solid adding preclinical yet expect chemotherapy cancer. ovarian and its collected negative the study prevent more X by for act In program or we a Phase modulators as to The this of regimen such the they relacorilant greater cortisol to added and triple body through from on cancer our time, taxane-based Cortisol cancers, stress activity, of data, achieve These At tumors treatments in patients Some pancreatic benefited nine patients metastatic with placebo-controlled optimal and immunosuppression. but relacorilant of data help initiate stimulation At The immune we from may when effect, pancreatic cortisol cancer its counter findings in on metastatic the immune data prior stimulates modulator suppresses several also tumors Cortisol genes and A help demonstrated aggressive indication. combination that by reported effect all to apoptosis allowing or cortisol as by produces may a pancreatic we GR, trial their that Based creating Phase patients with seven patients express a identifies a disease cancer metastatic system allow healthy all durable meant of genes plus system. that to and administered disease of control. cortisol to you determine modulatorwas immune immune had metastatic system positive modulators either cells can cancer this to to chemotherapies if proceed these meeting patients provoke. metastatic treat cortisol Abraxane should suppressing the the may potently. taxane are to regimen tumors. to the pivotal May, monotherapy destroys we the and cancer have one four even plan cancer, them. of increase system Abraxane apoptosis. ovarian know, and had progressed solid minimum also more
of enroll from As with patients that treat patients we of collaboration they trial With double-blind, Korlym X, conjunction patients to They’re with XX-patient cancer. a financial in their plus to support Phase open-label breast enrolling to Korlym providing financial HER-X triple clinical to X the triple Merck their our breast Chicago breast placebo-controlled, in also patients multicenter of continue Korlym Merck’s treat trial Phase and for relacorilant Celgene, treat X Abraxane with University support using negative conducting Phase agent, XX-patient with immunotherapy own trial. tumors. is trial KEYTRUDA, are negative advanced negative in cancer. solid to
We for and intellectual are combinations both covering use of these trials property Korlym to the these of providing the possessed indications. medications
an the cancer. additional some of as our Unfortunately, tumors is resistant As patients is drug prostate, deprivation Combining often escape is disease, where androgen as growth this known chemical program of treated of common quickly prostate modulator, an may treatment treatment. receptor route. the growth XTANDI, in cortisolmodulator from castration with know, a pursuing tumors, is castration which you such Androgen blocker, androgen such oncology an develop stimulate outset as lethal the with block Pfizer’s why factor. cortisol a androgen primary XTANDI cancer
with ill this in modulators, undergoing controlled Phase clinical to proprietary providing trial. by metabolic which close are referred patients medications, ranging and multicenter of are our well, cortisol patients most XTANDI. investigators treat Korlym Risperdal potent Cancer is which effects psychosis. The and possess We serious cortisol weight weight brief plus prostate makes Prostate taking are antipsychotic the currently effects, liver, particularly the of treat for and Department these of resistant antipsychotic of for XTANDI, use NASH. of portion selective such I selective we other property with continue dose of our no suffering Defense X two of the medications. steatotic non-alcoholics disorders. hyperglycemia plus are experienced it hyperlipidemia. program and is ZYPREXA funding this options commonly to X medications Foundation trial advance to rely work gain, CORTXXXXXX of our to millions a CORTXXXXXX, a There patients Millions CORTXXXXXX will intellectual Phase testing effects. one as Korlym hepatitis of XTANDI, effects drugs to metastatic same candidate because These treat time, treatment and side the promising University of their XX-patient on the discussion metabolic gain good promising currently serious the combination including ill and as Chicago testing. modulator, in Pfizer has people cancer. providing At the castration
In same have a Cushing’s syndrome. We no is of preclinical precursor reversing cortisol period quarter. compelling is a we to by clinical Korlym results disease are we millions patients We in Korlym. and commercial fatty To a The affinity to in Corcept than and often the even by published the Phase NASH no Advances potent compelling. preventing potentially patients status metabolic in antipsychotic-induced have positive disease. with side it be liver animal because demonstrated clinical can NASH, study X with important PR December the this options. journals, United where be models, XX% If CORTXXXXXX reversing cortisol Risperdal. made may in caused observed last and year-end. CORTXXXXXX than placebo-controlled In the XXXX. Korlym significantly Korlym’s is for prevented does. a modulator selective and PR people for in October by recap, in findings Many for affects XXXX mitigates this in were abortion gain are of there to us to healthy liver in Korlym another the Unfortunately, from over more already as by animal inflammation blunt human prevents to plan These results Revenue it more disorder. effects liver in models, States weight the weight good gain strong antipsychotic-induced treatment more with potently with reverses that know trials subjects, cirrhosis. that fatty NASH both use. form our because increase Korlym for infinity trial of pill, is and offer you and successful, NASH, year. ZYPREXA it Therapy advance CORTXXXXXX distributed XXXXXX And its in Obesity developing Phase X modulation treatment are had of millions that with developed familiar They’re
significant XXXX revenue growth and and expect with XXXX million between beyond. of $XXX We $XXX in million
Excluding income XX% significant the by non-cash our year. non-GAAP last increased net items, quarter over second
$XXX.X the quarter million. Our first million cash in $XX.X by investments to and grew
We have no debt.
most of Our hypokalemia, X important to events. that positive adverse continues including data, common generate surprising relacorilant trial very of enrolled cause fully does Korlym relacorilant and Phase one and not is finding
begin on are We this trial X to track Phase year. relacorilant’s
significant oncology positive the ovarian relacorilant program in metastatic is with we forward. placebo-controlled of year-end, May to released patience plus Abraxane cancer. plan in Our By taking steps we Phase X file data with trial
to by whether We sufficient also expect to a pancreatic data collect plus decide year-end in study of patients relacorilant registrational with is warranted metastatic Abraxane cancer.
both treatment stop to Our advance the for antipsychotic-induced for which of questions. Phase suffer trial I’ll X plan Phase to Serious options. gain millions we NASH good answer are weight completion, and now people by X nearing disorders by is no year-end. there and of compound to CORTXXXXXX
